A partir de cette page vous pouvez :
| Retourner au premier écran avec les dernières notices... |
Détail de l'auteur
Auteur Mereckiene J
Documents disponibles écrits par cet auteur
Ajouter le résultat dans votre panier Affiner la rechercheDifferences in national influenza vaccination policies across the European Union, Norway and Iceland 2008-2009 / Mereckiene J in Eurosurveillance. European communicable disease monthly [Euro Surveill], Vol. 15, N° 44 (04/11/2010)
Titre : Differences in national influenza vaccination policies across the European Union, Norway and Iceland 2008-2009 Type de document : Article scientifique Auteur(s) : Mereckiene J ; Cotter S ; D'Ancona F ; Giambi C ; Nicoll A ; Levy Bruhl D ; Lopalco PL ; Weber JT ; Johansen K ; Dematte L ; Salmaso S ; Stefanoff P ; Greco D ; Dorleans F ; Polkowska A ; O'Flanagan D Appartenance auteur(s) InVS DMI Année de publication : 2010 Article en page(s) : pii=19700 Langues : Anglais (eng)
in Eurosurveillance. European communicable disease monthly [Euro Surveill] > Vol. 15, N° 44 (04/11/2010) . - pii=19700Mots-clés : Grippe ; Vaccination ; Politique vaccination ; Union Européenne ; Norvège ; Islande Résumé : In 2009 the second cross-sectional web-based survey was undertaken by the Vaccine European New Integrated Collaboration Effort (VENICE) project across 27 European Union (EU) member states (MS), Norway and Iceland (n=29) to determine changes in official national seasonal influenza vaccination policies since a survey undertaken in 2008 and to compare the estimates of vaccination coverage between countries using data obtained from both surveys. Of 27 responding countries, all recommended vaccination against seasonal influenza to the older adult population. Six countries recommended vaccination of children aged between six months and PMID Pubmed : Pubmed : 21087586 Corpus : Production scientifique InVS Lien(s) externe(s) : http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19700 Permalink : http://opac.invs.sante.fr/index.php?lvl=notice_display&id=476 [article]Documents numériques
10487_PSAdobe Acrobat PDF
Titre : Health technology assessments on human papillomavirus vaccinations in Europe: a survey from VENICE network Type de document : Article scientifique Auteur(s) : Dorleans F ; Levy Bruhl D ; Giambi C ; D'Ancona F ; La Torre G ; Cotter S ; Mereckiene J ; Stefanoff P ; Appelgren E ; the Vaccine European New Integrated Collaboration Effort (VENICE II) project gatekeepers group Appartenance auteur(s) InVS DMI Année de publication : 2012 Article en page(s) : 3-12 Langues : Anglais (eng)
in Italian journal of public health [Ital J Public Health] > Vol. 9, N° 1 [01/03/2012] . - 3-12Mots-clés : HPV ; Vaccination ; Réseau surveillance ; Europe ; Calendrier vaccinal Résumé : Background: VENICE II is a project funded in 2008 by the European Centre for Disease Prevention and Control to collect information on the national vaccination programmes, to increase their knowledge and to know the impact of new vaccines introduced in member states (MS). In 2006-2007, two vaccines against human papillomavirus (HPV) were authorized in Europe. Methods: An online survey was carried out to investigate the decision-making process undertaken regarding the potential introduction of the HPV vaccinations into MS national immunization programmes as well as to investigate the modalities of implementation of the vaccination programmes. There were specific questions about health technology assessment and reports of the countries that had carried them out were reviewed. Results: In 21 of the 29 MS, the national advisory body recommended to introduce HPV vaccination in their national immunization schedule and in 18 countries introduced it. Only 6 countries have realized a health technology assessments (HTA) report, each one with different methodology, but in all of them both vaccines show positive evaluations. Conclusion: From the available HTA, HPV vaccination is cost-effective under the assumption of a lifelong protection. Screening programme for cervical cancer and HPV vaccination programme should be always complementary. Organizational aspects need to be taken into account to improve the vaccination. HPV vaccination should target girls before the debut of their sexual life. Instead HPV vaccination of boys has not been demonstrated as bringing significant epidemiological benefits and has not been shown as being cost-effective.
Traduction du résumé : Venice II est un projet financé en 2008 par le Centre européen de prévention et contrôle des maladies. Il a pour objectif de recueillir des données sur les programmes nationaux de vaccination, afin d'accroître leurs connaissances et connaître l'impact des nouveaux vaccins introduits dans les États membres (EM). En 2006-2007, deux vaccins contre le papillomavirus humain (HPV) ont été autorisés en Europe. Une enquête en ligne a été réalisée pour étudier le processus de prise de décision mis en place sur l'introduction potentielle de vaccins contre le HPV dans les programmes nationaux de vaccination des Etats membres et pour analyser les modalités de mise en œuvre des programmes de vaccination. Des questions précises sur l'évaluation des technologies de la santé ont été soulevées et les rapports des pays qui les avaient menées ont été examinés.
Résultats: L’organe consultatif national a recommandé d'introduire la vaccination contre le HPV dans le calendrier national de vaccination de 21 Etats membres sur 29, et 18 Etats membres pays ont introduit cette vaccination. Seuls six pays ont publié des rapports d’évaluations des technologies de la santé (ETS), chacun avec une méthodologie différente, mais dans chacun, les vaccins montrent des évaluations positives. Selon les ETS disponibles, la vaccination contre le HPV est rentable dans l'hypothèse d'une protection à vie. Le programme de dépistage du cancer du col de l'utérus et le programme de vaccination contre le HPV doivent toujours être complémentaires. Les aspects organisationnels doivent être pris en compte pour améliorer la vaccination. La vaccination contre le HPV doit cibler les filles avant le début de leur vie sexuelle. En revanche, rien ne permet d’indiquer que la vaccination contre le HPV chez les garçons est rentable ou qu’elle apporte un bénéfice épidémiologique significatif. (Traduction effectuée par la Cellule de Valorisation Editoriale – CeVE- de l’InVS)Corpus : Production scientifique InVS Permalink : http://opac.invs.sante.fr/index.php?lvl=notice_display&id=10572 [article]
Titre : Hepatitis B immunisation programmes in European Union, Norway and Iceland: Where we were in 2009 ? Type de document : Article scientifique Auteur(s) : Mereckiene J ; Cotter S ; Lopalco P ; D'Ancona F ; Levy Bruhl D ; Giambi C ; Johansen K ; Dematte L ; Salmaso S ; Stefanoff P ; O'Flanagan D Appartenance auteur(s) InVS DMI Année de publication : 2010 Article en page(s) : 4470-7 Langues : Anglais (eng)
in Vaccine > Vol. 28 (06/05/2010) . - 4470-7Mots-clés : Hépatite B ; Politique vaccination ; Vaccination ; Union Européenne ; Norvège ; Islande Résumé : In January 2009 25 European Union (EU) Member States (MSs), Norway and Iceland, participated in a survey seeking information on national hepatitis B vaccination programmes. Details of vaccination policy, schedule, population groups targeted for vaccination, programme funding, vaccine coverage and methods of monitoring of vaccine coverage were obtained. Twenty (74%) countries reported that they have a universal hepatitis B vaccination programme, in addition to immunisation of at risk groups; seven (26%) countries recommend HBV for high risk groups only (with some inter-country variation on groups considered at high risk). Among countries without universal hepatitis B vaccination programmes, the major factor for non-introduction is low disease endemicity.(R.A.) PMID Pubmed : Pubmed : 20451643 Lien externe DOI : DOI : 10.1016/j.vaccine.2010.04.037 Corpus : Production scientifique InVS Permalink : http://opac.invs.sante.fr/index.php?lvl=notice_display&id=676 [article]
Titre : Influenza A(H1N1)pdm09 vaccination policies and coverage in Europe Type de document : Article scientifique Auteur(s) : Mereckiene J ; Cotter S ; Weber JT ; Nicoll A ; D'Ancona F ; Lopalco PL ; Johansen K ; Wasley AM ; Jorgensen P ; Levy Bruhl D ; Giambi C ; Stefanoff P ; Dematte L ; O Flanagan D ; the Vaccine European New Integrated Collaboration Effort (VENICE) project gatekeepers group Appartenance auteur(s) InVS DMI Année de publication : 2012 Article en page(s) : pii=20064 Langues : Anglais (eng)
in Eurosurveillance. European communicable disease monthly [Euro Surveill] > Vol. 17, N° 4 [26/01/2012] . - pii=20064Mots-clés : Nouvelle grippe A (H1N1) ; Vaccination ; Politique vaccination ; Couverture vaccinale ; Union Européenne ; Norvège ; Islande Résumé : In August 2010 the Vaccine European New Integrated Collaboration Effort (VENICE) project conducted a survey to collect information on influenza A(H1N1)pdm09 vaccination policies and vaccination coverage in the European Union (EU), Norway and Iceland. Of 29 responding countries, 26 organised national pandemic influenza vaccination and one country had recommendations for vaccination but did not have a specific programme. Of the 27 countries with vaccine recommendations, all recommended it for healthcare workers and pregnant women. Twelve countries recommended vaccine for all ages. Six and three countries had recommendations for specific age groups in children and in adults, countries for specific adult age groups. Most countries recommended vaccine for those in new risk groups identified early in the pandemic such as morbid obese and people with neurologic diseases. Two thirds of countries started their vaccination campaigns within a four week period after week 40/2009. The reported vaccination coverage varied between countries from 0.4% to 59% for the entire population (22 countries); 3% to 68% for healthcare workers (13 countries); 0% to 58% for pregnant women (12 countries); 0.2% to 74% for children (12 countries). Most countries identified similar target groups for pandemic vaccine, but substantial variability in vaccination coverage was seen. The recommendations were in accordance with policy advice from the EU Health Security Committee and the World Health Organization. (R.A.) PMID Pubmed : Pubmed : 22297139 Corpus : Grippe A(H1N1)/Production scientifique InVS Lien(s) externe(s) : http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=20064 Permalink : http://opac.invs.sante.fr/index.php?lvl=notice_display&id=10433 [article]Documents numériques
10433_PSAdobe Acrobat PDF
Titre : National seasonal influenza vaccination survey in Europe, 2008 Type de document : Article scientifique Auteur(s) : Mereckiene J ; Cotter S ; Nicoll A ; Levy Bruhl D ; Ferro A ; Tridente G ; Zanoni G ; Berra P ; Salmaso S ; O'Flanagan D Appartenance auteur(s) InVS DMI Année de publication : 2008 Langues : Anglais (eng)
in Eurosurveillance. European communicable disease monthly [Euro Surveill] > Vol. 13, N° 43 (23/10/2008)Mots-clés : Grippe ; Vaccination ; Réseau surveillance ; Enquête transversale ; Couverture vaccinale ; Europe Résumé : A cross-sectional survey was undertaken with the European Union (EU) Member States and Norway and Iceland to describe seasonal influenza immunisation in the 2006-7 season, in particular to identify country-specific recommendations for risk groups, obtain vaccine uptake information and allow comparison with global recommendations. A standardised questionnaire was completed electronically by each country's project gatekeeper. Of the 29 countries surveyed, 28 recommended seasonal influenza vaccination for older age groups (22 for those aged > 65 years), and in one country vaccine was recommended for all age groups. All countries recommended vaccinating patients with chronic pulmonary and cardiovascular diseases and most countries advised to immunise patients with haematologic or metabolic disorders (n=28), immunologic disorders (n=27) and renal disease (n=27), as well as residents of long-term care facilities (n=24). Most countries recommended vaccination for staff in hospitals (n=25), long-term care facilities (n=25) and outpatient clinics (n=23), and one-third had such recommendations for workers in essential (n=10), military (n=10) and veterinary services (n=10) and poultry industry (n=13). Eight countries recommended vaccine for pregnant women; and five advised to vaccinate children (with age limits ranging from 6 months to 5 years). Twenty countries measured influenza vaccine uptake among those aged > 65 years (range 1.8%-82.1%), seven reported uptake in healthcare workers (range 14%-48%) and seven assessed coverage in persons with underlying medical conditions (range 27.6%-75.2%). The data provided by this study can assist EU states to assess and compare their influenza vaccination programme performance with other countries. The information provides a comprehensive overview of policies and programmes and their outcomes and can be used to inform joint discussions on how the national policies in the EU might be standardised in the future to achieve optimal coverage. Annual surveys could be used to monitor changes in these national policies. (R.A.) Corpus : Production scientifique InVS Permalink : http://opac.invs.sante.fr/index.php?lvl=notice_display&id=3288 [article]Documents numériques
7597_PSAdobe Acrobat PDF
